-
-
-
-
-
-
-
VistaGen Therapeutics (VTGN) Reports Positive Results from Phase 2A Pilot Study of PH15
-
-
-
-
-
-
-
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan
-
-
-
-
-
-
-
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
-
-
-
-
-
-
-
Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline Update
-
-
-
-
-
-
-
VistaGen Therapeutics Reports Fiscal 2019 Second Quarter Financial Results
-
1,155,357 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

